Acute myeloblastic leukemia achieving complete remission with amifostine alone

Basit Öğe Kaydı
dc.authorid0000-0002-4075-6692en_US
dc.contributor.authorÖztürk, Ahmet
dc.contributor.authorOrhan, Bülent
dc.contributor.authorEtiz, Durmuş
dc.contributor.authorYaylacı, Mustafa
dc.contributor.authorÜskent, Necdet
dc.date.accessioned2024-07-12T21:05:20Z
dc.date.available2024-07-12T21:05:20Z
dc.date.issued2002en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractAmifostine, a phosphorylated thiol-amine, is known as a cytoprotective agent especially for cisplatin containing chemotherapies. Apart from the cytoprotective role, Amifostine could also be used in the treatment of hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloblastic leukemia (AML), as a treatment option or for potentiating the effects of cytotoxic agents. We tried to use Amifostine in a patient with AML, which did not respond to conventional cytotoxic chemotherapy and aimed to publish the results. The patient was a 77-year-old male patient, he was diagnosed as AML by peripheral blood smear and bone marrow aspiration. Treatment commenced with low dose cytosine arabinoside (Ara-C) but the therapy should have ceased due to patient intolerance. The patient refused further therapy and he was offered to have Amifostine treatment. Amifostine was administered 200 mg/m2 three times a week, with ciprofloxacin, pentoxifyllin and dexamethasone. Dramatic response was obtained after 8 weeks of administration. Blast rate was reduced from 35 to 7% in bone marrow aspiration; pancytopenia was restored to normal levels. This remission was maintained through 8 more weeks. Amifostine treatment was restarted after he relapsed but this time he did not respond to the treatment and died of gastrointestinal bleeding on the 8th week of treatment.en_US
dc.identifier.citationÖztürk, A., Orhan, B., Türken, O., Etiz, D., Yaylacı, M. ve Üskent, N. (2002). Acute myeloblastic leukemia achieving complete remission with amifostine alone. Leukemia & Lymphoma, Taylor Francis Online. 43(2), s. 451-453.en_US
dc.identifier.endpage453en_US
dc.identifier.issn1042-8194\1029-2403
dc.identifier.issue2en_US
dc.identifier.startpage451en_US
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/11999588/
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3890
dc.identifier.volume43en_US
dc.institutionauthorTurken, Orhan
dc.language.isoenen_US
dc.publisherTaylor Francis Onlineen_US
dc.relation.ispartofLeukemia & Lymphomaen_US
dc.relation.isversionof10.1080/10428190290006341en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY02190
dc.titleAcute myeloblastic leukemia achieving complete remission with amifostine aloneen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu